<DOC>
	<DOCNO>NCT00296309</DOCNO>
	<brief_summary>Primary objective study compare renal function well incidence renal dysfunction , incidence death , graft loss acute rejection . Secondary Objective compare efficacy safety profile two regimen elderly renal transplant patient .</brief_summary>
	<brief_title>Comparing Efficacy &amp; Safety Tacrolimus &amp; MMF With/Without Induction Elderly Following Kidney Transplantation .</brief_title>
	<detailed_description>The use tacrolimus-based primary immunosuppression elderly renal transplant recipient efficacious safe , particularly combination MMF , seem associate low mortality graft loss rate classic cyclosporin protocol . Nevertheless , efficacy safety tacrolimus monotherapy , double triple therapy MMF , well induction therapy new anti-IL2 receptor antibody adequately use control trial elderly renal transplant patient . There scarce information age-associated immune responsiveness aged-adapted immunosuppressive regimen describe .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients minimum 60 year age end stage kidney disease suitable candidate primary renal transplantation retransplantation eligible study . Patients receive kidney transplant , cadaveric living donor ( HLA identical ) compatible ABO blood type include . Patient immunological high risk Cold ischemia time great 30 hour . Patient significant liver disease Patient allergic intolerant study medication Patient donor know HIV positive . Patient malignancy history malignancy Patient significant , uncontrolled concomitant infection</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Tacrolimus</keyword>
	<keyword>Kidney Transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Adult</keyword>
	<keyword>Treatment Outcomes</keyword>
</DOC>